0 182

Cited 132 times in

Nivolumab in NSCLC: latest evidence and clinical potential

Authors
 Raghav Sundar  ;  Byoung-Chul Cho  ;  Julie R. Brahmer  ;  Ross A. Soo 
Citation
 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol.7(2) : 85-96, 2015 
Journal Title
 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 
ISSN
 1758-8340 
Issue Date
2015
Keywords
immune checkpoint modulator ; nivolumab ; non-small cell lung cancer ; programmed death-1 ; programmed death-1 ligand
Abstract
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
Full Text
http://tam.sagepub.com/content/7/2/85.abstract
DOI
10.1177/1758834014567470
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/140780
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links